LONG BEACH, Calif. — Patients treated with Encelto who had smaller baseline ellipsoid zone area loss had better treatment response, according to a post hoc analysis presented at the American Society of Retina Specialists annual meeting.
Encelto (revakinagene taroretcel-lwey, Neurotech Pharmaceuticals) was approved in March by the FDA for the treatment of macular telangiectasia type 2 (MacTel) after undergoing investigation in two identical phase 3 trials.
“The two clinical trials showed differences in response between trial A and trial B,” Sophie J. Bakri, MD, told Healio. “This